CEO Chris Viehbacher steers Sanofi clear of drugs for Alzheimer's disease

Any company that can develop a drug even partially effective against Alzheimer's disease will strike a gold mine. One analyst estimates the opportunity to be $20 billion, but most attempts so far have been costly failures. Think Pfizer ($PFE) and Johnson & Johnson's ($JNJ) bapineuzumab and Eli Lilly's ($LLY) solanezumab, both of which flamed out in late-stage trials. Don't think Sanofi ($SNY), though, because CEO Chris Viehbacher says the French drugmaker is not interested in going down that path until the science of the disease is better understood. "We really, at best, partially understand the cause of the disease. It's hard to come up with meaningful targets," he said. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.